Neurogene, Inc. (NGNE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$38.60+2.63%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NGNE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue clinical development of NGN-401 for Rett syndrome, complete dosing, report registrational trial topline data in 2H 2027, and prepare for BLA submission.
Stated as a priority in 3 quarters including 2026-Q1 and 2026-Q2 and a June 2026 press release. Management completed dosing of 25 participants in the Embolden registrational trial, exceeding the target, and expects topline data in the second half of 2027. They initiated PPQ runs to support a BLA submission expected by year-end 2026. This trajectory matches management's stated development milestones and regulatory preparation, indicating delivering progress.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Topline data from Embolden registrational trial anticipated in 2H 2027; initiated PPQ campaign to support BLA submission.”
“On track to complete dosing in Embolden registrational trial in second quarter of 2026; continuing commercial-readiness activities.”
Preserve and extend cash runway to support ongoing clinical development and commercial readiness through at least first quarter of 2029.
Stated in 3 quarters including 2025-Q3, 2026-Q1, and 2026-Q2. The company raised approximately $144 million in a July 2026 public offering, increasing pro forma cash to about $360.2 million as of 2026-Q2, extending the cash runway from early 2028 to first quarter 2029. This reflects delivering on the priority to maintain a strong cash position to fund operations.
“Extended cash runway into 1Q 2029 with oversubscribed financing of approximately $144 million gross proceeds.”
“Strong cash position provides runway through first quarter of 2028.”
“Strong cash position provides runway through first quarter of 2028.”
Manage operating expenses and control net losses while investing in NGN-401 development and commercial readiness.
Stated in 3 quarters including 2025-Q2, 2026-Q1, and 2026-Q2. Operating expenses increased with R&D rising from $19.4M in 2025-Q2 to $25.5M in 2026-Q2, driven by NGN-401 development and commercial activities. Net loss increased from $22.0M to $34.5M over the same period. Management continues to manage expenses while investing in growth, indicating ongoing focus but increasing losses.
“R&D expenses $25.5M, G&A expenses $11.2M, net loss $34.5M for 2026-Q2.”
“R&D expenses $25.2M, G&A expenses $8.2M, net loss $30.9M for 2026-Q1.”
“Net loss was $22.0M for 2025-Q2; R&D and G&A expenses lower than 2026 periods.”
Continue progressing clinical trials and development activities for gene therapy candidates.
Over the trailing year it converted 1.26x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates (low R² over the window).
6 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.